StockNews.com began coverage on shares of Organovo (NASDAQ:ONVO – Free Report) in a research note published on Tuesday morning. The firm issued a sell rating on the medical research company’s stock.
Organovo Stock Performance
Shares of ONVO opened at $0.55 on Tuesday. Organovo has a 1 year low of $0.51 and a 1 year high of $2.05. The stock has a market capitalization of $7.86 million, a PE ratio of -0.34 and a beta of 0.68. The stock has a 50-day simple moving average of $0.78 and a 200-day simple moving average of $0.94.
Organovo (NASDAQ:ONVO – Get Free Report) last issued its quarterly earnings results on Friday, May 31st. The medical research company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.13. The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.08 million. Analysts predict that Organovo will post -1.4 EPS for the current year.
About Organovo
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Read More
- Five stocks we like better than Organovo
- What is the Nikkei 225 index?
- Should You Invest in Bitcoin? Pros and Cons
- Do ETFs Pay Dividends? What You Need to Know
- Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts
- What Are Dividends? Buy the Best Dividend Stocks
- Shell Stock: Oil & Gas Giant Committed to Buybacks and Dividends
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.
